CN115397849A - 减少患有认知衰退的患者中的β-淀粉样蛋白单体水平的方法 - Google Patents

减少患有认知衰退的患者中的β-淀粉样蛋白单体水平的方法 Download PDF

Info

Publication number
CN115397849A
CN115397849A CN202180027929.1A CN202180027929A CN115397849A CN 115397849 A CN115397849 A CN 115397849A CN 202180027929 A CN202180027929 A CN 202180027929A CN 115397849 A CN115397849 A CN 115397849A
Authority
CN
China
Prior art keywords
subject
months
amyloid
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180027929.1A
Other languages
English (en)
Chinese (zh)
Inventor
S·卡塔拉诺
N·伊佐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cognition Therapeutics Inc
Original Assignee
Cognition Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cognition Therapeutics Inc filed Critical Cognition Therapeutics Inc
Publication of CN115397849A publication Critical patent/CN115397849A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202180027929.1A 2020-02-13 2021-02-12 减少患有认知衰退的患者中的β-淀粉样蛋白单体水平的方法 Pending CN115397849A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062976325P 2020-02-13 2020-02-13
US62/976,325 2020-02-13
PCT/US2021/018023 WO2021163613A1 (en) 2020-02-13 2021-02-12 Method of decreasing amyloid beta monomer levels in patients with cognitive decline

Publications (1)

Publication Number Publication Date
CN115397849A true CN115397849A (zh) 2022-11-25

Family

ID=77292728

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180027929.1A Pending CN115397849A (zh) 2020-02-13 2021-02-12 减少患有认知衰退的患者中的β-淀粉样蛋白单体水平的方法

Country Status (8)

Country Link
US (1) US20230098944A1 (https=)
EP (1) EP4103604A4 (https=)
JP (2) JP2023513220A (https=)
KR (1) KR20220142477A (https=)
CN (1) CN115397849A (https=)
AU (1) AU2021218735A1 (https=)
IL (1) IL295427A (https=)
WO (1) WO2021163613A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025055549A1 (en) * 2024-01-24 2025-03-20 Shanghai University of Medicine and Health Sciences An isoindol-sulfilimine compound and use as a sigma-2 receptor inhibitor thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2692258C2 (ru) 2014-01-31 2019-06-24 Когнишн Терапьютикс, Инк. Композиции изоиндолина и способы лечения нейродегенеративного заболевания
WO2024196799A2 (en) * 2023-03-17 2024-09-26 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
WO2026030341A1 (en) * 2024-07-29 2026-02-05 Cognition Therapeutics, Inc. Zervimesine for treating neurodegenerative disease

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101103969A (zh) * 2002-12-24 2008-01-16 神经化学（国际）有限公司 治疗β淀粉样蛋白相关疾病的治疗性制品
CN101193628A (zh) * 2005-04-12 2008-06-04 神经化学（国际）有限公司 淀粉样蛋白抑制性化合物的药物制剂
CN106163516A (zh) * 2014-01-31 2016-11-23 考格尼申治疗股份有限公司 异吲哚啉组合物和治疗神经变性疾病的方法
WO2019089988A1 (en) * 2017-11-01 2019-05-09 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
CN112567039A (zh) * 2018-08-07 2021-03-26 大日本住友制药株式会社 阿尔茨海默氏病的诊断药物和诊断方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018156883A1 (en) * 2017-02-23 2018-08-30 Board Of Regents, The University Of Texas System Methods of treatment for cancer, sterol homeostasis, and neurological diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101103969A (zh) * 2002-12-24 2008-01-16 神经化学（国际）有限公司 治疗β淀粉样蛋白相关疾病的治疗性制品
CN101193628A (zh) * 2005-04-12 2008-06-04 神经化学（国际）有限公司 淀粉样蛋白抑制性化合物的药物制剂
CN106163516A (zh) * 2014-01-31 2016-11-23 考格尼申治疗股份有限公司 异吲哚啉组合物和治疗神经变性疾病的方法
WO2019089988A1 (en) * 2017-11-01 2019-05-09 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
CN112567039A (zh) * 2018-08-07 2021-03-26 大日本住友制药株式会社 阿尔茨海默氏病的诊断药物和诊断方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KELSIE M. LABARBERA等: "A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer’s disease using an indwelling CSF catheter", 《TRANSLATIONAL NEURODEGENERATION》, vol. 12, 12 May 2023 (2023-05-12), XP021318590, DOI: 10.1186/s40035-023-00358-w *
MICHAEL GRUNDMAN等: "A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer\'s disease", 《ALZHEIMER\'S & DEMENTIA: TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS》, vol. 5, 23 January 2019 (2019-01-23), pages 20 - 26 *
李晓康: "多靶点抗AD活性化合物设计合成与活性研究和3-芳基-3-羟基吲哚酮合成方法学研究", 《中国知网》, 15 September 2018 (2018-09-15) *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025055549A1 (en) * 2024-01-24 2025-03-20 Shanghai University of Medicine and Health Sciences An isoindol-sulfilimine compound and use as a sigma-2 receptor inhibitor thereof
US12371405B1 (en) 2024-01-24 2025-07-29 Shanghai University of Medicine and Health Sciences Isoindol-sulfilimine compound and use as a sigma-2 receptor inhibitor thereof
AU2024339613B2 (en) * 2024-01-24 2025-11-06 Shanghai University of Medicine and Health Sciences An isoindol-sulfilimine compound and use as a sigma-2 receptor inhibitor thereof

Also Published As

Publication number Publication date
US20230098944A1 (en) 2023-03-30
JP2026041805A (ja) 2026-03-10
WO2021163613A1 (en) 2021-08-19
JP2023513220A (ja) 2023-03-30
EP4103604A1 (en) 2022-12-21
IL295427A (en) 2022-10-01
AU2021218735A1 (en) 2022-09-01
KR20220142477A (ko) 2022-10-21
EP4103604A4 (en) 2024-03-27

Similar Documents

Publication Publication Date Title
CN115397849A (zh) 减少患有认知衰退的患者中的β-淀粉样蛋白单体水平的方法
US10434109B2 (en) Compositions for treating neurological disorders
JP4767982B2 (ja) 末梢または中枢神経障害およびサイトカイン過剰産生の治療のためのｋ−２５２ａ誘導体の使用
CN102065858B (zh) 使用唑尼沙胺和阿坎酸治疗阿尔茨海默病和相关病症的组合组合物
US20200338040A1 (en) Methods for treating alzheimer's disease and related disorders
TWI659017B (zh) 吲哚基及吲哚啉基異羥肟酸於治療神經退化病症或認知缺乏之用途
EP3813816B1 (en) Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid in the treatment of fragile x syndrome or fragile x-associated tremor/ataxia syndrome
WO2011050095A2 (en) Prevention and treatment of post-operative cognitive dysfunction (pocd)
RU2841658C1 (ru) Способ снижения уровней мономеров бета-амилоида у пациентов со снижением когнитивных способностей
TWI770608B (zh) 藥學組合物及其於治療帕金森氏症之用途
KR102901908B1 (ko) 운동신경세포 질환의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
HK40083593A (en) Method of decreasing amyloid beta monomer levels in patients with cognitive decline
US12311005B2 (en) Pharmaceutical compositions and uses thereof in treating Parkinson's disease
US11957692B2 (en) Clomipramine for the treatment of Alzheimer's Disease
JP2024538454A (ja) アルツハイマー病を予防又は治療する医薬組成物
WO2026052068A1 (zh) 药物组合物的用途
CN120459095A (zh) 氨基吡啶类物质抑制α-突触核蛋白聚集和路易小体形成的用途
WO2025186837A1 (en) A synergistic bioactive composition for controlling neuromuscular pain and repairing nerve damage
CN120305240A (zh) 4-羟基扁桃酸类化合物用于制备预防或治疗阿尔茨海默病的药物的用途
TW202448432A (zh) 肌萎縮性側索硬化症（ａｌｓ）的治療
HK40077546B (zh) 药学组合物及其於治疗帕金森氏症的用途
HK40050398B (en) Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid in the treatment of fragile x syndrome or fragile x-associated tremor/ataxia syndrome
HK40050398A (en) Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid in the treatment of fragile x syndrome or fragile x-associated tremor/ataxia syndrome
MXPA99000278A (en) Use of derivative of k-252a for the treatment of central peripheral nerve disorders and citoqu overproduction
HK40021759B (zh) 具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40083593

Country of ref document: HK